APA (7th ed.) Citation

Sharman, J. P., Liberati, A. M., Ishizawa, K., Khan, T., Robbins, J., Alcasid, A., . . . Aurer, I. (2020). A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 34(2), 171-181. https://doi.org/10.1007/s40259-019-00398-7

Chicago Style (17th ed.) Citation

Sharman, Jeff P., Anna Marina Liberati, Kenichi Ishizawa, Tahira Khan, Jeffery Robbins, Ann Alcasid, Julie Ann Rosenberg, and Igor Aurer. "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals, and Gene Therapy 34, no. 2 (2020): 171-181. https://doi.org/10.1007/s40259-019-00398-7.

MLA (9th ed.) Citation

Sharman, Jeff P., et al. "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals, and Gene Therapy, vol. 34, no. 2, 2020, pp. 171-181, https://doi.org/10.1007/s40259-019-00398-7.